Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbrdn Regulatory News (ABDN)

Share Price Information for Abrdn (ABDN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.05
Bid: 155.55
Ask: 155.90
Change: 0.10 (0.06%)
Spread: 0.35 (0.225%)
Open: 154.80
High: 156.50
Low: 152.25
Prev. Close: 154.95
ABDN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

2023 AGM Voting Results Update

3 Nov 2023 09:00

RNS Number : 2458S
abrdn PLC
03 November 2023
 

abrdn plc ('the Company')

2023 Annual General Meeting Voting Results - Update Statement

 

At the 2023 AGM, while all resolutions were passed, five resolutions received less than 80% of votes cast in favour of the resolution.

 

The results of the vote were primarily driven by a small number of shareholders, with the significant majority of shareholders who voted, voting in favour of the resolutions.

 

Following the AGM, the Chair, Sir Douglas Flint, and the Senior Independent Director (SID), Jonathan Asquith, have met with shareholders representing more than 80% of the shares voted against the resolutions, to ensure we understand their views. A summary of the resolutions and key areas of shareholder concern are detailed in the table below.

 

 

Resolution

%age

Key areas of concern

Resolution 7D:

To re-elect Catherine Bradley CBE as a Director

 

75.89

Concerns with the number of external mandates held.

 

Resolution 9:

To authorise the Directors to issue further shares

 

76.67

Concerns regarding shareholder dilution.

 

Resolution 10 (Special):

To disapply share pre-emption rights

 

78.21

Concerns regarding shareholder dilution.

 

Resolution 11 (Special):

To give authority for the Company to buy back up to 14.99% of its issued ordinary shares

 

75.41

Concerns regarding share repurchases, resulting in shareholding breaching certain thresholds.

 

Resolution 12:

To authorise the Directors to allot shares in relation to the issuance of Convertible Bonds

 

78.05

Concerns regarding shareholder

dilution.

 

 

Resolution 7D relates to the re-election of Catherine Bradley as a Director. One major shareholder applies more stringent requirements than the prevailing proxy advisor guidelines in relation to the number of external mandates held. The number of external mandates held by each Director are within the requirements of the proxy advisor guidelines and in line with market practice.

 

The Nomination and Governance Committee keeps under review all existing or planned external commitments of Directors to assess their ability to meet the necessary time commitment and whether there are any conflicts of interest to address. The Company is satisfied that Catherine Bradley is able to provide the required commitment to abrdn and to continue to make a valuable contribution to the Company.

 

We note that the authorities sought by the Company under resolutions 9, 10,11 and 12 are in line with, or lower than, the maximum recommended levels contained within the relevant share capital management guidelines and prevailing voting guidelines of leading corporate governance agencies. The majority of our shareholders are supportive of the authorities sought, which follow standard market practice in the UK.

 

The Company only retains these authorities to provide flexibility in the capital management of the Company and would only exercise these authorities if it were considered in the best interests of shareholders.

 

The Company intends to continue constructive dialogue with its major shareholders to understand any concerns they may have, and the Chair and SID would welcome any relevant feedback from any other shareholders in relation to these matters, or any others.

 

3 November 2023

 

 

Enquiries:

 

Group Secretariat

Paul McKenna

 

+44 (0) 7736 853 801

 

Media Relations

Andrea Ward

 

 

+44 (0) 7876 178 696

 

Institutional Equity Investors

Sarah Moody

 

Corbin Chaplin

 

 

+44 (0) 7721 679 892

 

+44 (0) 7774 332 428

 

LEI: 0TMBS544NMO7GLCE7H90

Classification: 3.1. Additional regulated information required to be disclosed under the laws of the United Kingdom

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAKFAEDDDFFA
Date   Source Headline
22nd Aug 20237:00 amRNSTransaction in Own Shares
21st Aug 20232:06 pmRNSDirector/PDMR Shareholding
21st Aug 20237:00 amRNSTransaction in Own Shares
18th Aug 20234:11 pmRNSHolding(s) in Company
18th Aug 20231:33 pmRNSHolding(s) in Company
18th Aug 202310:25 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
18th Aug 20237:00 amRNSTransaction in Own Shares
17th Aug 202312:18 pmRNSForm 8.3 - Dechra Pharmaceuticals PLC
17th Aug 20237:00 amRNSTransaction in Own Shares
16th Aug 20235:22 pmRNSHolding(s) in Company
16th Aug 20233:00 pmRNSHolding(s) in Company
16th Aug 202310:58 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
16th Aug 20237:00 amRNSTransaction in Own Shares
15th Aug 20237:00 amRNSTransaction in Own Shares
14th Aug 202311:03 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
14th Aug 20237:00 amRNSTransaction in Own Shares
11th Aug 20232:51 pmRNSForm 8.3 - Dechra Pharmaceuticals PLC
11th Aug 20237:00 amRNSTransaction in Own Shares
10th Aug 20237:00 amRNSTransaction in Own Shares
9th Aug 202310:55 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
8th Aug 20232:05 pmRNSForm 8.3 - Dechra Pharmaceuticals PLC
8th Aug 20232:00 pmRNSForm 8.3 - LondonMetric Property plc
8th Aug 20237:00 amRNSUpdate on Share Repurchase Programme
8th Aug 20237:00 amRNSHalf-year Report - Part 3 of 3
8th Aug 20237:00 amRNSHalf-year Report - Part 2 of 3
8th Aug 20237:00 amRNSHalf-year Report - Part 1 of 3
8th Aug 20237:00 amRNSTransaction in Own Shares
7th Aug 202311:01 amRNSForm 8.3 - LondonMetric Property plc
7th Aug 20237:43 amRNSHolding(s) in Company
7th Aug 20237:00 amRNSTransaction in Own Shares
4th Aug 20233:50 pmRNSHolding(s) in Company
4th Aug 202311:01 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
4th Aug 20237:00 amRNSTransaction in Own Shares
3rd Aug 20235:25 pmRNSHolding(s) in Company
3rd Aug 202310:49 amRNSForm 8.3 - Blancco Technology Group plc
3rd Aug 202310:40 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
3rd Aug 20237:00 amRNSTransaction in Own Shares
2nd Aug 202310:40 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
2nd Aug 20237:00 amRNSTransaction in Own Shares
1st Aug 202311:58 amRNSTotal Voting Rights
1st Aug 20237:00 amRNSTransaction in Own Shares
31st Jul 202312:21 pmRNSForm 8.3 - Dechra Pharmaceuticals PLC
31st Jul 20237:00 amRNSTransaction in Own Shares
28th Jul 20239:24 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
28th Jul 20237:00 amRNSTransaction in Own Shares
27th Jul 202311:30 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
27th Jul 202310:00 amRNSDirectorate Change
27th Jul 20237:00 amRNSTransaction in Own Shares
26th Jul 202310:47 amRNSForm 8.3 - Dechra Pharmaceuticals PLC
26th Jul 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.